AIT Therapeutics (OTCMKTS:AITB) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Wednesday.

Separately, Zacks Investment Research upgraded AIT Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 7th.

OTCMKTS:AITB opened at $4.85 on Wednesday. The company has a market capitalization of $42.13 million, a price-to-earnings ratio of -1.61 and a beta of -0.32. AIT Therapeutics has a 12-month low of $2.05 and a 12-month high of $5.50.

AIT Therapeutics (OTCMKTS:AITB) last released its quarterly earnings data on Wednesday, February 13th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.32. On average, equities research analysts forecast that AIT Therapeutics will post -0.78 EPS for the current fiscal year.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Featured Story: What is the Stochastic Momentum Index (SMI)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.